electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
electroCore (Nasdaq: ECOR) will report fourth quarter and full year 2025 financial results after market close on Thursday, March 19, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
electroCore (Nasdaq: ECOR) will report fourth quarter and full year 2025 financial results after market close on Thursday, March 19, 2026. Management will host a webinar at 4:30 PM EDT to review results and take investor questions; dial-in and webinar access details are provided.
Details
News Market Reaction – ECOR
On Mar 9, the day this news came out, ECOR closed 3.07% below the previous close.
Data tracked by StockTitan Argus for the Mar 9 session.
Key Figures
- Earnings date
- March 19, 2026
- Scheduled Q4 and full-year 2025 results release
- Results release time
- After market close
- Q4 and full-year 2025 results on March 19, 2026
- Webinar time
- 4:30 PM EDT
- Management call to discuss Q4 and FY2025 results
- Current price
- $6.85
- Price before earnings-date announcement
- 1-day move
- -8.91%
- Price change in prior 24 hours
- 52-week high
- $15.68
- Pre-announcement 52-week trading range
- 52-week low
- $4.16
- Pre-announcement 52-week trading range
- Market cap
- $60,129,191
- Equity value prior to earnings-date news
Historical Context
-
Announced PTSD study using gammaCore Sapphire with up to 40 adult participants.
-
Preliminary 2025 revenue guidance showing ~26% growth to about $31.8–$32.0M.
-
Peer‑reviewed TAC‑STIM study showing significant mood and performance improvements.
-
Announcement of participation in Canaccord Genuity MedTech and Digital Health forum.
-
Record Q3 2025 net sales growth and raised full-year 2025 revenue guidance.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2025, after the close of the market on Thursday, March 19, 2026.
Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below:
Thursday, March 19, 4:30 PM EDT
Dial-In: (646) 931-3860
Webinar ID: 886 9421 4883
Passcode: 014212
Registration Link: Click here to participate and ask questions on the call.
About electroCore, Inc.
electroCore, Inc. and its subsidiaries (“electroCore” or the “Company”) is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Truvaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
For more information, visit www.electrocore.com.
Contact
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.